Abstract:
PROBLEM TO BE SOLVED: To provide a compound having the activity useful for treating symptoms caused or aggravated by neovascularization, and to provide a pharmaceutical composition containing the compound. SOLUTION: The compound is a peptide of the formula:A 0 -A 1 -A 2 -A 3 -A 4 -A 5 -A 6 -A 7 -A 8 -A 9 -A 10 ( wherein, A 0 is H or an acyl; A 10 is OH or an amino acid amido; and A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 and A 9 are each a specific aminoacyl residue ). COPYRIGHT: (C)2006,JPO&NCIPI
Abstract translation:待解决的问题:提供具有可用于治疗由新生血管形成引起或加重的症状的活性的化合物,并提供含有该化合物的药物组合物。 解决方案:该化合物是下式的肽:A 0 SB> -A -A 2 SB> / SB> -A 4 SB> -A 5 SB> -A 6 SB> -A 7 SB> -A 8 < / SB> -A -A 10 SB>(其中,A 0 SB>是H或酰基; A SB < 是OH或氨基酸酰氨基; A 1 SB>,A 2 SB>,A 3 SB>,A 4 SB> A,SB SB 7,SB SB 8,SB SB 8,SB SB 8,SB SB 8,SB SB 8,SB 8, 特定的氨基残基)。 版权所有(C)2006,JPO&NCIPI
Abstract:
PROBLEM TO BE SOLVED: To provide a new antiangiogenic compound useful to treat a condition which is occasioned or worsened by angiogenesis. SOLUTION: The compound is a peptide having the formula: A 0 -A 1 -A 2 -A 3 -A 4 -A 5 -A 6 -A 7 -A 8 -A 9 -A 10 (wherein A 0 is selected from hydrogen and an acyl group; A 10 is a hydroxy group or an amino acid amide; and A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , and A 9 are each an aminoacyl residue such as pyroGlu-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH3). COPYRIGHT: (C)2006,JPO&NCIPI
Abstract translation:要解决的问题:提供一种新的抗血管生成化合物,可用于治疗由血管发生引起或恶化的病症。 解决方案:该化合物是具有下式的肽:A 0 SB> -A -A 2 SB> / SB> -A 4 SB> -A 5 SB> -A 6 SB> -A 7 SB> -A 8 < 其中A 0 SB>选自氢和酰基; A 10 SB> SB>是羟基或氨基酸酰胺; A 1 SB>,A 2 SB>,A 3 SB>,A SB>,A 5 SB>,A 6 SB>,A 7 SB>,A 8 SB> / SB>各自为氨酰基残基,如pyroGlu-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH3)。 版权所有(C)2006,JPO&NCIPI
Abstract:
Compounds having the formula are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.
Abstract:
Compounds of formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
Abstract translation:描述了可用于治疗由血管生成引起或加剧的病症的式(SEQ ID NO:1)的化合物。 还公开了包含这些化合物的药物组合物,使用这些化合物的治疗方法,以及抑制血管发生的方法。
Abstract:
Compounds having the formula are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.
Abstract:
Disclosed are 3'-N-desmethyl-3'-N-susbstituted-6-O-methyl-11-deoxy-11, 12-cyclic carbamate erythromycin A derivatives which are antagonists of lutenizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.
Abstract:
Compounds of formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
Abstract translation:描述了可用于治疗由血管生成引起或加剧的病症的式(SEQ ID NO:1)的化合物。 还公开了包含这些化合物的药物组合物,使用这些化合物的治疗方法,以及抑制血管发生的方法。
Abstract:
Compounds having the formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
Abstract translation:描述了用于治疗由血管发生引起的或由血管发生加剧的病症的具有式(SEQ ID NO:1)的化合物。 还公开了包含这些化合物的药物组合物,使用这些化合物的治疗方法以及抑制血管生成的方法。
Abstract:
Peptides of formula (I) Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11, are useful for inhibiting angiogenesis. Also disclosed are angiogenesis-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.